Skip to main content
HYUNDAI BIOSCIENCE CO., LTD. logo

HYUNDAI BIOSCIENCE CO., LTD. — Investor Relations & Filings

Ticker · 048410 ISIN · KR7048410005 KO Professional, scientific and technical activities
Open in API
Filings indexed 288 across all filing types
Latest filing 2024-12-20 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 048410

About HYUNDAI BIOSCIENCE CO., LTD.

http://www.hyundaibioscience.com/eindex…

HYUNDAI BIOSCIENCE CO., LTD. is a biotechnology company focused on developing innovative therapeutics using its proprietary drug delivery system (DDS) technology. The company's core science is based on organic-inorganic hybrid technologies designed to safely and effectively deliver active ingredients. Its main development pipeline includes CP-COV03, a broad-spectrum antiviral agent that enhances cellular autophagy to combat viral infections, and Polytaxel, an anticancer drug candidate developed with polymer transfer technologies to reduce toxicity. The company's primary focus is on creating novel treatments for viral diseases and cancer.

Recent filings

Filing Released Lang Actions
전환가액의조정
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing regarding the adjustment of the conversion price of convertible bonds (9th series) for Hyundai Bioscience. It details the change in conversion price, the number of convertible shares, the reason for the adjustment (market price decline), and the calculation methodology. This falls under capital structure changes related to financing instruments, which is best classified as a Capital/Financing Update.
2024-12-20 Korean
주주명부폐쇄기간또는기준일설정
Notice of Dividend Amount Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date and shareholder register closure for the purpose of an upcoming Annual General Meeting (AGM). It does not contain the full meeting materials or proxy statements, but rather serves as a formal notice of the procedural step required for shareholder voting. Given its nature as a regulatory notification of a corporate event, it fits best under the RNS (Regulatory Filings) category.
2024-12-17 Korean
유상증자1차발행가액결정
Share Issue/Capital Change Classification · 100% confidence The document is an official announcement from Hyundai Bioscience regarding the determination of the first issue price for a paid-in capital increase (rights offering). It details the number of shares, the calculated price, and the methodology for determining the final issue price. This falls under the category of share issuance and capital changes.
2024-12-16 Korean
[기재정정]주요사항보고서(유상증자결정)
Capital/Financing Update Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) from Hyundai Bioscience regarding a 'Decision on Paid-in Capital Increase' (유상증자결정). It details the correction of the issuance price (1차발행가액 정정) and provides comprehensive information on the capital increase, including share allocation methods, subscription dates, and underwriting details. This falls under the category of capital structure changes and financing activities.
2024-12-16 Korean
[발행조건확정]증권신고서(지분증권)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Securities Registration Statement' (증권신고서) filed with the Financial Services Commission (금융위원회) in South Korea. It details a capital increase (rights offering) for Hyundai Bioscience, including the determination of issuance conditions, pricing, and use of proceeds. This is a formal regulatory filing related to a capital change/share issuance, which falls under the 'Share Issue/Capital Change' category.
2024-12-16 Korean
[기재정정]투자설명서
Capital/Financing Update Classification · 98% confidence The document is a '투자설명서 정정신고' (Amendment to the Investment Prospectus) filed by Hyundai Bioscience. It details changes to the offering price, total offering amount, and use of proceeds following the determination of the 1st issuance price. This is a formal regulatory filing related to a capital raise (rights offering/public offering), which falls under the category of Proxy Solicitation & Information Statement (PSI) as it provides detailed information to shareholders regarding a corporate action requiring their participation or vote, or more broadly, it is a formal prospectus document used for capital raising.
2024-12-16 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.